Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

March 17, 2014

Primary Completion Date

September 21, 2017

Study Completion Date

September 21, 2017

Conditions
Chronic Iron Overload
Interventions
DRUG

Deferiprone

Deferiprone 80 mg/mL oral solution

DRUG

Deferasirox

Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg

Trial Locations (22)

Unknown

Hospital 'Ihsan Çabej', Lushnjë

"Qendra Spitalore Universitare Nene Tereza Tirane", Tirana

Department of Medical and Public health Services of the Ministry of Health, Nicosia

Alexandria University Hospital - Faculty of Medicine, Alexandria

Cairo University Faculty of Medicine, Cairo

Zagazig University Hospitals, Zagazig

National And Kapodistrian University of Athens, Athens

Centro di Thalassemia, Ospedale Civile di Lentini, Lentini

Università di Bari - Facoltà di Medicina, Bari

ASL Cagliari Ospedale Regionale per le Microcitemie, Cagliari

Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania

"Presidio Ospedaliero Annunziata, Centro di Studi della Microcitemia", Cosenza

A.O.Universitaria Meyer, Florence

Clinica Pediatrica Policlinico di Modena, Modena

"Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli", Napoli

Azienda Ospedaliera di Padova, Padua

Ospedali Riuniti Villa Sofia - Cervello, Palermo

U.O.C. Ematologia - Emoglobinopatie, Ospedale G. Di Cristina, Palermo

Clinica Pediatrica Università - ASL 1 D.H per Talassemia, Sassari

Centre National de Greffe de Moelle Osseuse Tunis, Tunis

Barts Health NHS Trust, London

Queen's Hospital, Romford

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Consorzio per Valutazioni Biologiche e Farmacologiche

OTHER

NCT01825512 - Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients | Biotech Hunter | Biotech Hunter